Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
Cancer Treat Rev. 2021 Jul;98:102224. doi: 10.1016/j.ctrv.2021.102224. Epub 2021 May 19.
Ovarian cancer is a deadly malignancy with a growing therapeutic armamentarium, though achieving sustained benefit in the clinic remains largely elusive. Through biomarker and genetic analysis, several pathways of resistance and sensitivity to commonly used therapeutics have been identified, expanding the potential of identifying unique drug combinations and indicating new directions for improving clinical outcomes. Here, we review the mechanisms of angiogenic response and antiangiogenic therapy in ovarian cancer, as well as the interactions it exhibits with the immune and DNA damage response pathways. We discuss results from clinical trials examining the combinations of antiangiogenics, PARP inhibitors, and immune checkpoint inhibitors are also discussed, as well as several ongoing trials.
卵巢癌是一种致命的恶性肿瘤，其治疗方法不断增加，但在临床上仍难以实现持续获益。通过生物标志物和基因分析，已经确定了对常用治疗药物的几种耐药和敏感途径，这增加了确定独特药物组合的潜力，并为改善临床结果指明了新的方向。在这里，我们回顾了卵巢癌中血管生成反应和抗血管生成治疗的机制，以及它与免疫和 DNA 损伤反应途径的相互作用。我们还讨论了临床试验的结果，这些试验研究了抗血管生成药物、PARP 抑制剂和免疫检查点抑制剂的联合应用，以及几项正在进行的试验。
